Does empagliflozin increase serum creatinine levels?

Does Empagliflozin Increase Serum Creatinine?

Yes, empagliflozin causes a small, transient, and reversible increase in serum creatinine that typically occurs within the first 2-4 weeks of initiation, but this does not represent true kidney injury and should not prompt discontinuation of therapy. 1, 2

Understanding the Creatinine "Dip"

The initial rise in serum creatinine with empagliflozin reflects a hemodynamic effect, not tubular damage:

• Mechanism: Empagliflozin reduces intraglomerular pressure through tubuloglomerular feedback, leading to a temporary decrease in eGFR of approximately 3-5 mL/min/1.73 m² 3
• Timeline: This occurs within the first 2-4 weeks of treatment 1, 3
• Reversibility: After this initial dip, eGFR typically stabilizes and the long-term trajectory shows kidney protection 1
• Not true injury: This is distinct from acute tubular necrosis—urine microscopy and novel biomarkers (NGAL, KIM-1) can differentiate true tubular damage from hemodynamic changes 2

Clinical Management Algorithm

When initiating empagliflozin:

1. Expect and accept a creatinine increase of up to 0.3 mg/dL or eGFR decline of 3-5 mL/min/1.73 m² in the first month
2. Do not discontinue empagliflozin based solely on this initial creatinine rise 1, 3
3. Continue therapy even if eGFR falls below the initiation threshold (20 mL/min/1.73 m²), unless the patient develops intolerance or requires kidney replacement therapy 1, 3
4. Monitor context: Assess for true kidney injury only if there are concerning clinical features (sepsis, bleeding, hypotension) or abnormal urine microscopy 2

Evidence from Major Trials

The landmark kidney outcomes trials consistently demonstrated this pattern:

• CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials: All showed initial creatinine increases that were followed by long-term kidney protection 1, 4
• EMPA-REG OUTCOME: Empagliflozin reduced the risk of doubling of serum creatinine by 44% despite initial increases 4
• Trial protocols specifically allowed continuation of SGLT2 inhibitors when eGFR fell below initiation thresholds 1

Case Example from Guidelines

A 45-year-old woman with heart failure started on empagliflozin 10 mg had her creatinine increase from 1.2 to 1.5 mg/dL over 2 weeks, while her NT-proBNP improved from 1,400 to 900 pg/mL. The correct management is to continue both lisinopril and empagliflozin 2. The creatinine rise without tubular injury markers, combined with clinical improvement, indicates beneficial hemodynamic effects rather than harm.

Common Pitfalls to Avoid

• Do not reflexively stop empagliflozin when creatinine rises in the first month—this deprives patients of proven kidney and cardiovascular protection
• Do not confuse hemodynamic changes with acute kidney injury—look for clinical context and consider urine microscopy if concerned
• Do not require more frequent monitoring solely because of SGLT2 inhibitor use—standard CKD monitoring intervals are appropriate 3

Pharmacokinetic Considerations

From FDA labeling data: In patients with renal impairment, empagliflozin AUC increases (18% in mild, 20% in moderate, 66% in severe impairment) 5. However, this does not translate to increased toxicity—the drug remains safe and effective down to eGFR ≥20 mL/min/1.73 m² 1, 3.

The bottom line: The transient creatinine increase with empagliflozin is an expected pharmacodynamic effect that signals beneficial kidney hemodynamics, not kidney damage. Continue therapy to achieve the proven long-term benefits of reduced CKD progression, cardiovascular events, and mortality 1, 4, 6.